NASDAQ:SLDB

Solid Biosciences Q4 2025 Earnings Results & Report

Solid Biosciences logo
$6.23 -0.25 (-3.86%)
Closing price 04:00 PM Eastern
Extended Trading
$6.24 +0.01 (+0.16%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Solid Biosciences beat analyst earnings expectations in its Q4 2025 results, released March 19, 2026. The company reported EPS of -$0.50 versus the -$0.51 consensus estimate.

Earnings Announcement Details

Quarter
Q4 2025
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

Solid Biosciences EPS Results

Actual EPS
-$0.50
Consensus EPS
-$0.51
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

Solid Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Solid Biosciences Q4 2025 Earnings FAQ

Solid Biosciences (NASDAQ:SLDB) reported earnings of -$0.50 per share for Q4 2025, beating the consensus estimate of -$0.51. The report was announced on Thursday, March 19, 2026.

Solid Biosciences Earnings Headlines

William Blair Begins Coverage on Solid Biosciences (NASDAQ:SLDB)
ELON + YOU + DECEMBER 8TH
Elon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th. A free Masterclass claims to reveal what Musk filed with regulators and why he's working to keep it quiet.tc pixel
Solid Biosciences (SLDB) Gets a Buy from RBC Capital
See More Solid Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Solid Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Solid Biosciences and other key companies, straight to your email.

About Solid Biosciences

Solid Biosciences (NASDAQ:SLDB) is a biotechnology company developing genetic medicines for Duchenne muscular dystrophy and other serious neuromuscular and cardiac diseases. The company’s research focuses on gene-transfer approaches intended to address underlying causes of these conditions.

Its lead program, SGT-003, is an investigational gene therapy being developed for Duchenne muscular dystrophy. Solid Biosciences also has research programs targeting other rare diseases. These programs are in development, and its therapies have not been established as approved treatments.

Founded in 2013 and based in the United States, Solid Biosciences conducts research and clinical development in the rare-disease field. Its work includes evaluating investigational treatments through clinical studies.

View Solid Biosciences Profile